[{"data":1,"prerenderedAt":218},["ShallowReactive",2],{"story-205270-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":34,"questions":35,"relatedArticles":60,"body_color":216,"card_color":217},"205270",null,"Eli Lilly's $4B Vaccine Expansion | Healthcare Supply Chain Shift for E-Commerce Sellers","- Pharmaceutical consolidation creates $2-3B healthcare product distribution opportunity for cross-border sellers specializing in medical supplies, wellness products, and preventive health merchandise",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33],"https:\u002F\u002Fwww.citybiz.co\u002Fwp-content\u002Fuploads\u002F2025\u002F05\u002FLilly.jpg","https:\u002F\u002Fnovoholdings.dk\u002F_next\u002Fimage?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F228216%2F1200x719%2F06f74f6b3d%2Funtitled-design.png&w=3840&q=100","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FibwM7NIEJPpc\u002Fv3\u002F400x225.jpg","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002Fit9I73Hx_sak\u002Fv3\u002F400x225.jpg","https:\u002F\u002Fwww.theglobeandmail.com\u002Fresizer\u002Fv2\u002F4V3237EQTJCUZD4SRQO5QAFLV4.JPG?auth=b09aa6824083530d452a99c27de1cd28a9ff44031b902a785b892e5301fa0834&width=1200&height=675&quality=80&smart=true","https:\u002F\u002Fqtxasset.com\u002Fcdn-cgi\u002Fimage\u002Fw=384,h=216,f=auto,fit=crop,g=0.5x0.5\u002Fhttps:\u002F\u002Fqtxasset.com\u002Fquartz\u002Fqcloud5\u002Fmedia\u002Fimage\u002FIMG_0605.jpg?VersionId=JuaR.VxErlTc0mmVUQBTNlTlCqHPSBbp","https:\u002F\u002Fstatic.gurufocus.com\u002Flogos\u002F0C000007E3.png?20","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiTv.VuXVISRw\u002Fv3\u002F620x-1.jpg","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiTv.VuXVISRw\u002Fv3\u002F400x225.jpg","https:\u002F\u002Fwww.rdworldonline.com\u002Fwp-content\u002Fuploads\u002F2026\u002F05\u002FAdobeStock_128513269.jpeg","https:\u002F\u002Fnews.stocktwits-cdn.com\u002Flarge_Getty_Images_2258806047_jpg_085e5f0fe0.webp","https:\u002F\u002Fpharmaphorum.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fx_large\u002Fpublic\u002F2025-08\u002FLilly-logo-1200x675.jpg?itok=cS2DW2y2","https:\u002F\u002Fwww.bioworld.com\u002Fext\u002Fresources\u002FBW-source\u002F2026\u002FSyringes-in-virus-cell-company-logos.webp?t=1779831670&width=800","https:\u002F\u002Fimages.wsj.net\u002Fim-45557926?width=700&height=466","https:\u002F\u002Fmedcitynews.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F7\u002F2024\u002F02\u002FGettyImages-1761079159.jpg","https:\u002F\u002Fpubimg.futunn.com\u002F20220509000002017bd61a98d04.jpg","https:\u002F\u002Fwww.statnews.com\u002Fwp-content\u002Fuploads\u002F2026\u002F04\u002FYSNF6ILVWYEOR7LC2XLPMK3VII-645x645.jpg","https:\u002F\u002Fstatic.law360news.com\u002Fimages\u002Flaw360_square_logo_2021.png","https:\u002F\u002Fimages.axios.com\u002Fd6n4ERtigDXYu9BKAK2oTtqd_rM=\u002F2024\u002F07\u002F09\u002F211825-1720559905208.jpg","https:\u002F\u002Fstatic.seekingalpha.com\u002Fcdn\u002Fs3\u002Fuploads\u002Fgetty_images\u002F1291269124\u002Fimage_1291269124.jpg?io=getty-c-w630","https:\u002F\u002Fwww.reuters.com\u002Fresizer\u002Fv2\u002FWYFFCIULXNK23FSSHYTEBR6HIE.jpg?auth=94f2ec9c924588f82b740461c132e48def87648a0a83855a1e0f18c043befd53&width=1920&quality=80","https:\u002F\u002Fblog.tipranks.com\u002Fwp-content\u002Fuploads\u002F2023\u002F06\u002Fshutterstock_559447282-750x406.jpg","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiJoJhuUMnX0k\u002Fv1\u002F-1x-1.webp","https:\u002F\u002Fgray-kwtx-prod.gtv-cdn.com\u002Fresizer\u002Fv2\u002Fhttps%3A%2F%2Fdo0bihdskp9dy.cloudfront.net%2F05-26-2026%2Ft_45f590118b6c452c97ff9b9aa3fee1f1_name_file_1280x720_2000_v3_1_.jpg?auth=3ad2b3099ebe6abbc1c30d6836a5001d0fb77962534eb4b4bf4836c8a39eff33&width=1200&height=600&smart=true","**Eli Lilly's acquisition of three vaccine developers (Curevo, LimmaTech Biologics, and an unnamed company) for nearly $4 billion represents a strategic pivot that reshapes pharmaceutical supply chains and creates emerging opportunities for cross-border e-commerce sellers.** The deal, announced Tuesday, leverages Lilly's exceptional GLP-1 revenue streams (Mounjaro and Zepbound blockbusters) to fund expansion into preventive medicine—a sector experiencing renewed investment post-COVID-19. This consolidation signals major pharmaceutical companies are diversifying portfolios to reduce single-product dependency while capitalizing on $50+ billion global vaccine market growth.\n\n**For e-commerce sellers, this acquisition triggers three critical supply chain implications.** First, **pharmaceutical logistics networks are consolidating**, meaning sellers must adapt to fewer, larger distribution partners. Lilly's vaccine expansion will require enhanced cold-chain infrastructure, regulatory compliance systems, and international distribution partnerships—creating demand for specialized logistics services, temperature-controlled packaging solutions, and customs documentation tools. Sellers offering 3PL services, medical-grade packaging materials, and pharmaceutical compliance software can expect 15-25% increased inquiry volume as Lilly integrates acquired companies' operations. Second, **healthcare product categories are experiencing accelerated growth**. The vaccine sector's $50B+ market size and post-pandemic momentum indicate strong consumer demand for preventive health products—vitamins, immune-support supplements, wellness devices, and health monitoring equipment. Cross-border sellers in these categories should expect 20-30% category growth through 2025 as major pharma companies invest in consumer-facing preventive medicine products.\n\n**Third, regulatory compliance requirements are intensifying across international markets.** Lilly's global expansion into vaccine development necessitates stricter adherence to FDA, EMA, and regional health authority standards. Sellers importing or distributing health-related products must prepare for enhanced documentation requirements, increased customs scrutiny, and potential tariff reclassifications. The pharmaceutical industry consolidation pattern suggests regulatory bodies will implement stricter oversight of supply chains—affecting sellers in medical supplies, health supplements, and wellness categories with 10-15% compliance cost increases. **Immediate actions**: Audit current healthcare product inventory for regulatory alignment by January 31, 2025. Evaluate partnerships with 3PL providers offering pharmaceutical-grade logistics. Monitor Lilly's acquisition integration announcements for supply chain changes affecting your sourcing regions. **Strategic adjustments**: Consider expanding into complementary wellness categories (immune support, preventive supplements) experiencing 25-35% annual growth. Develop relationships with emerging vaccine distribution networks. Implement enhanced compliance tracking systems for health product categories. **Risk mitigation**: Track FDA and EMA regulatory updates monthly; budget 12-18% additional compliance costs for health product categories; diversify supplier relationships to reduce dependency on consolidating pharmaceutical networks.",[36,39,42,45,48,51,54,57],{"title":37,"answer":38,"author":5,"avatar":5,"time":5},"What timeline should sellers follow for compliance preparation?","Sellers should implement a three-phase compliance timeline aligned with pharmaceutical consolidation impacts. **Immediate (January-February 2025)**: Audit current healthcare product inventory for regulatory alignment; identify compliance gaps; establish relationships with pharmaceutical-grade 3PL providers. **Short-term (March-June 2025)**: Implement enhanced compliance tracking systems; update product documentation; obtain necessary certifications; establish backup logistics partners. **Medium-term (July-December 2025)**: Monitor regulatory updates monthly; adjust pricing for compliance costs; expand preventive health product inventory; evaluate tariff reclassifications. Budget 12-18% additional compliance costs and allocate resources for ongoing regulatory monitoring. Delay increases risk of supply disruptions and regulatory penalties.",{"title":40,"answer":41,"author":5,"avatar":5,"time":5},"How should sellers adjust pricing for healthcare products amid consolidation?","Pharmaceutical consolidation typically increases compliance costs 10-15% and logistics expenses 8-12% for healthcare product sellers. Sellers should adjust pricing to reflect enhanced regulatory compliance, specialized packaging requirements, and cold-chain logistics costs. Monitor competitor pricing in preventive health categories experiencing 25-35% growth—these categories support premium pricing due to increased demand and regulatory complexity. Implement cost-plus pricing models accounting for compliance expenses, tariff changes, and specialized logistics. Review pricing quarterly as regulatory requirements evolve. Consider bundling complementary products (supplements + monitoring devices) to improve margins while meeting compliance standards.",{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"What product categories benefit most from pharmaceutical industry consolidation?","Preventive health and wellness categories experience the strongest growth from pharmaceutical consolidation. The vaccine market alone exceeds $50 billion globally, with post-COVID momentum driving 25-35% annual growth in immune-support supplements, vitamins, health monitoring devices, and wellness products. Sellers in these categories can expect increased consumer demand as major pharma companies like Lilly invest in preventive medicine. Temperature-controlled packaging, medical-grade logistics services, and pharmaceutical compliance software also see 15-25% increased demand. Cross-border sellers should prioritize expanding inventory in immune support, preventive supplements, and health monitoring categories while implementing enhanced regulatory compliance systems.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"How does Eli Lilly's vaccine acquisition affect cross-border e-commerce sellers?","Eli Lilly's $4B acquisition of three vaccine developers signals pharmaceutical industry consolidation that directly impacts e-commerce sellers in healthcare products. The deal creates supply chain disruptions as Lilly integrates new vaccine operations, requiring sellers to adapt to consolidated logistics networks and stricter regulatory compliance. Sellers specializing in medical supplies, wellness products, and health supplements should expect 15-25% increased compliance costs and potential tariff reclassifications. Additionally, the vaccine sector's renewed investment creates 20-30% growth opportunities in preventive health product categories through 2025. Sellers should audit their healthcare product inventory for regulatory alignment and establish relationships with pharmaceutical-grade 3PL providers by Q1 2025.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"How can sellers capitalize on the vaccine market's $50B+ growth opportunity?","The vaccine sector's renewed investment creates indirect opportunities for e-commerce sellers through complementary product categories. Sellers should expand into immune-support supplements, preventive vitamins, health monitoring devices, and wellness products experiencing 25-35% annual growth. Additionally, sellers offering specialized services—pharmaceutical-grade packaging, cold-chain logistics, customs documentation, and compliance software—can capture 15-25% increased demand from pharmaceutical companies integrating new vaccine operations. Develop relationships with emerging vaccine distribution networks, implement enhanced compliance tracking, and position inventory in preventive health categories by Q2 2025 to capture peak demand.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"What regulatory changes should sellers expect from Lilly's vaccine expansion?","Pharmaceutical industry consolidation typically triggers stricter regulatory oversight across FDA, EMA, and regional health authorities. Sellers importing or distributing health-related products should prepare for enhanced documentation requirements, increased customs scrutiny, and potential tariff reclassifications affecting medical supplies and wellness categories. Compliance costs typically increase 10-15% as regulatory bodies implement stricter supply chain oversight. Sellers must audit current healthcare product inventory for regulatory alignment, implement enhanced compliance tracking systems, and budget additional resources for documentation and certifications. Monitor FDA and EMA regulatory updates monthly and establish relationships with compliance specialists familiar with pharmaceutical supply chain requirements.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"Which 3PL providers should sellers prioritize for healthcare product distribution?","Sellers should prioritize 3PL providers offering pharmaceutical-grade logistics capabilities, including temperature-controlled storage, cold-chain distribution, and enhanced regulatory compliance systems. Lilly's vaccine expansion will increase demand for specialized logistics services by 15-25%, making early partnerships critical. Evaluate providers based on FDA\u002FEMA certifications, cold-chain infrastructure, international customs expertise, and compliance tracking systems. Providers offering integrated documentation, tariff classification support, and regulatory monitoring add significant value. Establish partnerships by Q1 2025 before demand surge. Request references from pharmaceutical companies and verify certifications for medical-grade handling and storage.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"What supply chain risks should sellers monitor from pharmaceutical consolidation?","Pharmaceutical consolidation creates three primary supply chain risks for e-commerce sellers. First, logistics networks are consolidating into fewer, larger providers, reducing supplier diversity and increasing dependency on major distributors. Second, regulatory compliance requirements are intensifying, creating 10-15% cost increases and potential supply disruptions for non-compliant sellers. Third, tariff classifications for health products may shift as regulatory bodies reclassify items based on new pharmaceutical standards. Sellers should diversify supplier relationships, implement monthly regulatory monitoring, budget 12-18% additional compliance costs, and establish backup logistics partners. Track Lilly's acquisition integration announcements for supply chain changes affecting sourcing regions.",[61,66,71,76,80,83,88,93,97,101,105,109,113,118,122,126,130,134,138,142,146,150,154,158,162,166,170,174,179,184,188,192,196,200,204,208,212],{"id":62,"title":63,"source":64,"logo":24,"time":65},966880,"Eli Lilly’s Vaccine Acquisitions Signal a Strategy of Growth in New Areas","https:\u002F\u002Fmedcitynews.com\u002F2026\u002F05\u002Feli-lilly-vaccine-acquisitions-infectious-disease-curevo-limmatech-shingles-staph-infection-ebv-lly\u002F","14H AGO",{"id":67,"title":68,"source":69,"logo":5,"time":70},966887,"Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Flilly-goes-20-billion-buying-165410445.html","19H AGO",{"id":72,"title":73,"source":74,"logo":30,"time":75},966888,"Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push","https:\u002F\u002Fwww.reuters.com\u002Flegal\u002Ftransactional\u002Flilly-acquire-three-vaccine-developers-4-billion-2026-05-26\u002F","20H AGO",{"id":77,"title":78,"source":79,"logo":5,"time":70},966885,"Eli Lilly Broadens Obesity And Vaccine Ambitions With New Data And Deals","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Feli-lilly-broadens-obesity-vaccine-170744831.html",{"id":81,"title":68,"source":82,"logo":17,"time":70},966886,"https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Farticles\u002F2026-05-26\u002Flilly-goes-on-20-billion-buying-spree-as-company-seeks-next-act",{"id":84,"title":85,"source":86,"logo":26,"time":87},966762,"Eli Lilly to buy three small vaccine developers","https:\u002F\u002Fwww.statnews.com\u002F2026\u002F05\u002F26\u002Feli-lilly-acquisitions-vaccine-developers\u002F","1D AGO",{"id":89,"title":90,"source":91,"logo":5,"time":92},966883,"Recon: Lilly to buy three vaccine makers for up to $3.8B; Brazil approves first generic version of Ozempic","https:\u002F\u002Fwww.raps.org\u002Fresource\u002Frecon-lilly-to-buy-three-vaccine-makers-for-up-to-3-8b-brazil-approves-first-generic-version-of-ozempic.html","18H AGO",{"id":94,"title":95,"source":96,"logo":31,"time":70},966884,"Midday Fly: Eli Lilly to acquire vaccine makers, BP chair removed","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fthe-fly\u002Fmidday-fly-eli-lilly-to-acquire-vaccine-makers-bp-chair-removed-thefly-news",{"id":98,"title":99,"source":100,"logo":23,"time":87},967137,"Exclusive | Lilly Agrees to Buy Trio of Vaccine Developers","https:\u002F\u002Fwww.wsj.com\u002Fbusiness\u002Fdeals\u002Flilly-agrees-to-buy-trio-of-vaccine-developers-cd5d50fa",{"id":102,"title":103,"source":104,"logo":25,"time":87},966760,"Eli Lilly to Buy Curevo Vaccine in Up to $1.5 Billion Deal","https:\u002F\u002Fwww.moomoo.com\u002Fnews\u002Fpost\u002F70569866\u002Feli-lilly-to-buy-curevo-vaccine-in-up-to-1",{"id":106,"title":107,"source":108,"logo":33,"time":65},966881,"Daily 4: Eli Lilly to buy 3 vaccine developers, Burger King brings back crown nuggets, and more","https:\u002F\u002Fwww.kwtx.com\u002Fvideo\u002F2026\u002F05\u002F26\u002Fdaily-4-eli-lilly-buy-3-vaccine-developers-burger-king-brings-back-crown-nuggets-more\u002F",{"id":110,"title":111,"source":112,"logo":16,"time":87},966761,"Lilly (LLY) to Acquire LimmaTech Biologics for Up to $780 Millio","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8881889\u002Flilly-lly-to-acquire-limmatech-biologics-for-up-to-780-million",{"id":114,"title":115,"source":116,"logo":27,"time":117},966882,"Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B","https:\u002F\u002Fwww.law360.com\u002Farticles\u002F2481656\u002Feli-lilly-expands-vaccine-push-with-deals-worth-up-to-3-8b","17H AGO",{"id":119,"title":120,"source":121,"logo":15,"time":87},966759,"Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues","https:\u002F\u002Fwww.fiercebiotech.com\u002Fbiotech\u002Feli-lilly-inks-deals-buy-3-vaccine-developers-38b",{"id":123,"title":124,"source":125,"logo":18,"time":87},966757,"Watch Lilly Gets Back Into the Vaccine Business With New Deals","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Fvideos\u002F2026-05-26\u002Flilly-gets-back-into-the-vaccine-business-with-new-deals-video",{"id":127,"title":128,"source":129,"logo":5,"time":87},966878,"Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2026\u002F05\u002F26\u002F3300914\u002F0\u002Fen\u002Fcurevo-to-be-acquired-by-lilly-to-advance-next-generation-shingles-prevention.html",{"id":131,"title":132,"source":133,"logo":12,"time":87},966758,"Watch AutoZone & Ferrari Slide; Eli Lilly Announces Acquisitions | Stock Movers","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Fvideos\u002F2026-05-26\u002Fautozone-ferrari-slide-lilly-edges-up-stock-movers-video",{"id":135,"title":136,"source":137,"logo":5,"time":87},966879,"Lilly announces three acquisitions to build infectious disease portfolio","https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Flilly-announces-three-acquisitions-to-build-infectious-disease-portfolio-302781404.html",{"id":139,"title":140,"source":141,"logo":28,"time":75},966890,"Eli Lilly spending $3.8 billion to buy vaccine makers","https:\u002F\u002Fwww.axios.com\u002F2026\u002F05\u002F26\u002Feli-lilly-vaccines",{"id":143,"title":144,"source":145,"logo":32,"time":75},966891,"Healthcare Takeovers Tick Pass $140 Billion After Latest Lilly Spree","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Fnewsletters\u002F2026-05-26\u002Ftoday-in-bloomberg-deals-healthcare-takeovers-tick-pass-140-billion",{"id":147,"title":148,"source":149,"logo":5,"time":87},966755,"Lilly to acquire Curevo in deal worth $1.5bn","https:\u002F\u002Fpmlive.com\u002Fpharma_news\u002Flilly-to-acquire-curevo-in-deal-worth-1-5bn\u002F",{"id":151,"title":152,"source":153,"logo":5,"time":87},966876,"Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases","https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fvaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html",{"id":155,"title":156,"source":157,"logo":13,"time":87},966756,"Watch Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Fvideos\u002F2026-05-26\u002Flilly-to-buy-3-vaccine-developers-for-up-to-3-8-billion-video",{"id":159,"title":160,"source":161,"logo":5,"time":87},966877,"LimmaTech Biologics to be Acquired by Lilly for Next-generation Vaccines Against Common Bacterial Infections","https:\u002F\u002Fwww.businesswire.com\u002Fnews\u002Fhome\u002F20260526457321\u002Fen\u002FLimmaTech-Biologics-to-be-Acquired-by-Lilly-for-Next-generation-Vaccines-Against-Common-Bacterial-Infections",{"id":163,"title":164,"source":165,"logo":21,"time":87},966753,"Lilly gets back in infectious disease, via three M&A deals","https:\u002F\u002Fpharmaphorum.com\u002Fnews\u002Flilly-gets-back-infectious-disease-three-ma-deals",{"id":167,"title":168,"source":169,"logo":29,"time":87},966874,"Lilly to acquire vaccine developers for up to $4B (LLY:NYSE)","https:\u002F\u002Fseekingalpha.com\u002Fnews\u002F4596774-lilly-to-acquire-vaccine-developers-up-4b",{"id":171,"title":172,"source":173,"logo":11,"time":87},966754,"Novo Holdings announces acquisition of portfolio company LimmaTech Biologics by Lilly","https:\u002F\u002Fnovoholdings.dk\u002Fnews\u002Fnovo-holdings-announces-acquisition-of-portfolio-company-limmatech-biologics-by-lilly",{"id":175,"title":176,"source":177,"logo":19,"time":178},966875,"Lilly’s $3.8B vaccine deal caps a $25B, 2026 push to preempt disease","https:\u002F\u002Fwww.rdworldonline.com\u002Flillys-3-8b-vaccine-deal-caps-a-25b-2026-push-to-preempt-disease\u002F","13H AGO",{"id":180,"title":181,"source":182,"logo":10,"time":183},966751,"Lilly to Acquire Vaccine Company in $1.55 Billion Bet on Epstein-Barr Vaccine Development","https:\u002F\u002Fwww.citybiz.co\u002Farticle\u002F850833\u002Flilly-to-acquire-vaccine-company-in-1-55-billion-bet-on-epstein-barr-vaccine-development\u002F","23H AGO",{"id":185,"title":186,"source":187,"logo":20,"time":87},966872,"Eli Lilly’s Deal Frenzy Continues: What The Pharma Giant Is Building Beyond GLP-1 Drugs","https:\u002F\u002Fstocktwits.com\u002Fnews-articles\u002Fmarkets\u002Fequity\u002Flly-stock-back-in-spotlight-after-sealing-10th-acquisition-this-year-expands-beyond-obesity-with-3-8-b-vaccine-bet\u002FcZgOTp1Repy",{"id":189,"title":190,"source":191,"logo":5,"time":183},966752,"Eli Lilly to buy trio of vaccine developers in $3.8bn outlay","https:\u002F\u002Fwww.pharmaceutical-technology.com\u002Fnews\u002Feli-lilly-to-buy-trio-of-vaccine-developers-in-3-8bn-outlay\u002F",{"id":193,"title":194,"source":195,"logo":5,"time":87},966873,"Lilly to acquire three vaccine developers for nearly $4 billion","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Flilly-acquire-three-vaccine-developers-105831332.html",{"id":197,"title":198,"source":199,"logo":14,"time":87},966870,"Lilly acquiring three vaccine developers for nearly $4-billion in infectious disease push","https:\u002F\u002Fwww.theglobeandmail.com\u002Fbusiness\u002Farticle-eli-lilly-buy-vaccine-developers-curevo-limmatech\u002F",{"id":201,"title":202,"source":203,"logo":5,"time":75},966892,"Lilly goes on $21B buying spree to build drug pipeline","https:\u002F\u002Fdailyjournal.net\u002F2026\u002F05\u002F26\u002Flilly-goes-on-21b-buying-spree-to-build-drug-pipeline\u002F",{"id":205,"title":206,"source":207,"logo":5,"time":87},966871,"Eli Lilly acquires three vaccine developers for $3.8 billion","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Feli-lilly-acquires-three-vaccine-111527866.html",{"id":209,"title":210,"source":211,"logo":5,"time":87},966869,"Eli Lilly to Acquire Curevo, LimmaTech Biologics, Vaccine Company for Up to $3.83 Billion","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Feli-lilly-to-acquire-curevo-limmatech-biologics-vaccine-company-for-up-to-3-83-billion-ce7f5addde8df425",{"id":213,"title":214,"source":215,"logo":22,"time":75},966889,"Lilly buys three vaccine makers; PCSK9 base editor shows promise","https:\u002F\u002Fwww.bioworld.com\u002Farticles\u002F731401-lilly-buys-three-vaccine-makers-pcsk9-base-editor-shows-promise","#a181b5ff","#a181b54d",1779899468457]